DEVELOPMENT OF A NINTEDANIB TECHNOSPHERE POWDER FOR TARGETED LUNG DELIVERY IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

被引：0
|
作者：
Hofmann, Thomas [1 ]
Grant, Marshall [1 ]
Ufer, Stefan [2 ]
Castagna, Michael [1 ]
Freeman, John [1 ]
机构：
[1] Mannkind, Danbury, CT USA
[2] Swabian, Raleigh, NC USA
来源：
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY | 2023年 / 36卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
E. 16
引用
收藏
页码：A16 / A16
页数：1
相关论文
共 50 条
  • [21] Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Fell, Charlene D.
    Huggins, J. Terrill
    Nunes, Hilario
    Sussman, Robert
    Valenzuela, Claudia
    Petzinger, Ute
    Stauffer, John L.
    Gilberg, Frank
    Bengus, Monica
    Wijsenbeek, Marlies
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [22] Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
    Kato, Motoyasu
    Nakamura, Takahiro
    Kono, Kana
    Haraguchi, Mizuki
    Yamada, Tomoko
    Ihara, Hiroaki
    Takahashi, Fumiyuki
    Takahashi, Kazuhisa
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [23] Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
    Ochi, Yusuke
    Kato, Motoyasu
    Fujioka, Masahiro
    Hayashi, Mika
    Takagi, Haruhi
    Takahashi, Kazuhisa
    RESPIROLOGY CASE REPORTS, 2020, 8 (07):
  • [24] Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
    José Antonio Rodríguez-Portal
    Drugs in R&D, 2018, 18 : 19 - 25
  • [25] Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
    Brown, Kevin K.
    Flaherty, Kevin R.
    Cottin, Vincent
    Raghu, Ganesh
    Inoue, Yoshikazu
    Azuma, Arata
    Huggins, John T.
    Richeldi, Luca
    Stowasser, Susanne
    Stansen, Wibke
    Schlenker-Herceg, Rozsa
    Maher, Toby M.
    Wells, Athol U.
    RESPIRATORY MEDICINE, 2019, 146 : 42 - 48
  • [26] Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
    Chennakesavulu, S.
    Mishra, A.
    Sudheer, A.
    Sowmya, C.
    Reddy, C. Suryaprakash
    Bhargav, E.
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 13 (01) : 91 - 100
  • [27] Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
    S.Chennakesavulu
    A.Mishra
    A.Sudheer
    C.Sowmya
    C.Suryaprakash Reddy
    E.Bhargav
    AsianJournalofPharmaceuticalSciences, 2018, 13 (01) : 91 - 100
  • [28] TREATMENT COST COMPARISON OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Ho, R.
    Rufino, C.
    Lisondo, C.
    Alves, M.
    VALUE IN HEALTH, 2017, 20 (09) : A893 - A893
  • [29] Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
    Mulholland, S. A.
    Al Jbour, K.
    Steer, H.
    Gutsche, M.
    Foley, N.
    Srivastava, R.
    Sharp, C.
    Adamali, H. I.
    Barratt, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [30] Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
    Bonella, Francesco
    Stowasser, Susanne
    Wollin, Lutz
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6407 - 6419
12345